---
document_datetime: 2024-07-24 16:26:17
document_pages: 16
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/mozobil-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: mozobil-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 11.343094
conversion_datetime: 2025-12-18 21:56:07.369616
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Mozobil

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                          | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IA/0055              | B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information | 09/05/2024                          | n/a                                         |                                  |           |
| N/0054               | Minor change in labelling or package leaflet not                                                                                                                               | 12/01/2024                          | 14/03/2024                                  | PL                               |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                    | connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                              |            |            |                        |                                   |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| IA/0053            | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 08/12/2023 | n/a        |                        |                                   |
| N/0052             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                             | 03/11/2023 | 14/03/2024 | Labelling and PL       |                                   |
| PSUSA/2451/ 202212 | Periodic Safety Update EU Single assessment - plerixafor                                                                                                                                                                                     | 31/08/2023 | n/a        |                        | PRAC Recommendation - maintenance |
| IB/0050            | B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier                                                                                                   | 31/07/2023 | n/a        |                        |                                   |
| IAIN/0049          | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                   | 13/04/2023 | 14/03/2024 | SmPC, Labelling and PL |                                   |
| N/0047             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                             | 09/11/2021 | 07/06/2022 | PL                     |                                   |
| IA/0046            | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                | 17/06/2021 | 07/06/2022 | Annex II and PL        |                                   |
| N/0045             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                             | 09/10/2020 | 07/06/2022 | PL                     |                                   |
| PSUSA/2451/        | Periodic Safety Update EU Single assessment -                                                                                                                                                                                                | 04/09/2020 | n/a        |                        | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| 201912    | plerixafor                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |            |    |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|
| IA/0044   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 20/05/2020 | n/a        |    |
| IA/0042   | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 18/02/2020 | n/a        |    |
| N/0041    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 18/02/2020 | 07/06/2022 | PL |
| II/0040/G | This was an application for a group of variations. B.I.a.1.c - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer uses a substantially different route of synthesis or manufacturing conditions B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method | 12/12/2019 | n/a        |    |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| B.I.b.1.c - Change in and/or limits of an AS, material/intermediate/reagent specification parameter corresponding test method B.I.b.1.c - Change in and/or limits of an AS, material/intermediate/reagent specification parameter corresponding test method B.I.b.1.d - Change in and/or limits of an AS, material/intermediate/reagent significant specification an obsolete parameter) B.I.b.1.h - Change in and/or limits of an AS, material/intermediate/reagent replacement (excl. Biol. specification parameter quality issue B.I.b.1.h - Change in and/or limits of an AS, material/intermediate/reagent replacement (excl. Biol. specification parameter quality issue B.I.b.2.e - Change in starting material/reagent/intermediate changes to a test procedure or addition) for the AS   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|             | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                             |            |            |                        |                    |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------|
| IA/0039     | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                            | 14/08/2019 | n/a        |                        |                    |
| II/0034     | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                                                                                                                                                                                                                                                           | 28/03/2019 | 13/05/2019 | SmPC and PL            |                    |
|             | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place | 23/01/2019 | n/a        |                        | IA/0038/G          |
| IG/1003     | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                                                                                                                               | 20/12/2018 | 13/05/2019 | SmPC, Labelling and PL |                    |
| IAIN/0036/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a for the FP - Secondary packaging                                                                                                                                                                                                                                                                            | 11/10/2018 | 13/05/2019 | Annex II and PL        | manufacturing site |

<div style=\"page-break-after: always\"></div>

|                    | site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                               |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                              |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0035            | B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information                                                                                                                            | 21/12/2017 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                              |
| II/0032            | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                         | 01/09/2017 | 19/10/2017 | SmPC and PL | Based on the results of study MSC12830 (MOZ11809), the recommended dose of plerixafor by subcutaneous injection (SC) is now according to a weight-based dosing, as follows: • 20 mg fixed dose or 0.24 mg/kg of body weight for patients weighing ≤83 kg (see section 5.2). • 0.24 mg/kg of body weight for patients weighing >83 kg. The results of the study are now detailed in section 5.3. RMP version 9.0 is accepted. |
| PSUSA/2451/ 201612 | Periodic Safety Update EU Single assessment - plerixafor                                                                                                                                                                                                                                                  | 20/07/2017 | 18/09/2017 | SmPC        | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/2451/201612.                                                                                                                                                                                                                                                                                    |
| II/0030/G          | This was an application for a group of variations. Update of section 4.4 of the SmPC in order to reflect the final report from study ARD12858 (MOZ23510) 'A pilot, exploratory, randomised, phase 2 safety study evaluating tumour cell (plasma cell) mobilisation and apheresis product contamination in | 22/06/2017 | 18/09/2017 | SmPC and PL | Update of section 4.4 of the SmPC in order to reflect the final report from study ARD12858 (MOZ23510) 'A pilot, exploratory, randomised, phase 2 safety study evaluating tumour cell (plasma cell) mobilisation and apheresis product contamination in plerixafor plus non-pegylated G- CSF mobilised patients and in non pegylated G-CSF alone mobilised patients' listed as a category 3 study in the RMP.                 |

<div style=\"page-break-after: always\"></div>

| plerixafor plus non-pegylated G-CSF mobilised patients and in non pegylated G-CSF alone mobilised patients' listed as a category 3 study in the RMP. Submission of the final report from study OBS13611 (MOZ18009), a multicenter, noninterventional registry designed to evaluate the long-term outcomes for patients who received plerixafor for stem cell mobilisation and completed hematopoietic stem cell transplantation (HSCT) compared with patients who received other mobilisation methods and completed HSCT, listed as a category 3 study in the RMP. Submission of the final report from study OBS13612 (MOZ19310), monitoring the plerixafor off-label transplant use, in patients and donors in EBMT centers performing autologous transplants and/or allogeneic transplants, listed as a category 3 study in the RMP. In addition, the MAH took this opportunity to update the local representatives in the Package Leaflet. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission   | Submission of the final report from study OBS13611 (MOZ18009), a multicenter, noninterventional registry designed to evaluate the long-term outcomes for patients who received plerixafor for stem cell mobilisation and completed hematopoietic stem cell transplantation (HSCT) compared with patients who received other mobilisation methods and completed HSCT, listed as a category 3 study in the RMP. Submission of the final report from study OBS13612 (MOZ19310), monitoring the plerixafor off-label transplant use, in patients and donors in EBMT centers performing autologous transplants and/or allogeneic transplants, listed as a category 3 study in the RMP. In addition, the MAH took this opportunity to update the local representatives in the Package Leaflet   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| IAIN/0033   | B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer                                                                                                                                                                                                                                                                                                                                       | 12/06/2017   | n/a   |                          |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|--------------------------|
| II/0026/G   | This was an application for a group of variations. B.II.b.1.d - Replacement or addition of a manufacturing site for the FP - Site which requires an initial or product specific inspection B.II.b.3.b - Change in the manufacturing process of the finished or intermediate product - Substantial changes to a manufacturing process that may have a significant impact on the quality, safety and efficacy                                                                                                                                          | 14/01/2016   | n/a   | of the medicinal product |
| II/0027/G   | This was an application for a group of variations. B.II.e.1.a.3 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Sterile medicinal products and biological/immunological medicinal products B.II.e.4.c - Change in shape or dimensions of the container or closure (immediate packaging) - Sterile medicinal products B.II.e.4.c - Change in shape or dimensions of the container or closure (immediate packaging) - Sterile medicinal products B.II.e.6.b - Change in any part of the (primary) | 17/12/2015   | n/a   |                          |

<div style=\"page-break-after: always\"></div>

|         | Change that does not affect the product information B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier   |            |            |             | product formulation -   |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------|
| IB/0028 | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                                      | 01/10/2015 | n/a        |             |                         |
| IA/0029 | B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation                                                                                                                                                                                                                                 | 24/09/2015 | n/a        |             |                         |
| N/0025  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                            | 14/07/2015 | 02/03/2016 | PL          |                         |
| IA/0024 | B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information                                                                                                                                                              | 21/05/2015 | n/a        |             |                         |
| IB/0023 | To update section 4.2 of the SmPC as requested by the PRAC/CHMP within LEG024 procedure in order to fulfil a post-authorisation measure resulting from the assessment of PSUR 07 (PSUV/0021). In addition, minor formatting amendments to SmPC and PL have been performed. (Safety/Efficacy) of Human and                                   | 24/03/2015 | 02/03/2016 | SmPC and PL | C.I.z - Changes         |

<div style=\"page-break-after: always\"></div>

|           | Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                  |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUV/0021 | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                                           | 24/07/2014 | 22/09/2014 | SmPC and PL                      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUV/0021.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| II/0020   | Submission of the final non-clinical study report to address FUM003.4/MEA003.4. The objective of the study was to investigate whether there is a difference in tumour engraftment and progression when injecting rodents with tumour cells which do not express CXCR4 compared with tumour cells expressing CXCR4. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 25/04/2014 | n/a        |                                  | The MAH submitted a study which aim was to investigate whether there was a difference in tumour engraftment and progression when injecting SCID mice with tumour cells which do not express CXCR4 compared with tumour cells expressing CXCR4. Results of this study indicate that expression of CXCR4 on tumour cells may enhance tumour engraftment and thus increase the risk of disease relapse. However, a conclusion on whether the risk of relapse due to contaminating tumour cells is greater following G-CSF + plerixafor when compared to G-CSF mobilisation alone cannot be drawn based on this experiment. |
| IG/0418   | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                                                                  | 11/04/2014 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| R/0019    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                          | 20/02/2014 | 11/04/2014 | SmPC, Annex II, Labelling and PL | Based on the review of the available information the CHMP is of the opinion that the quality, the safety and the efficacy of Mozobil continues to be adequately and sufficiently demonstrated and considers that the benefit/risk profile of this medicinal product continues to be favourable. The CHMP recommends the renewal of the Marketing Authorisation for Mozobil, subject to the conditions and obligations as laid down in Annex II to the Opinion. The CHMP recommends that the renewal be granted with                                                                                                     |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |            |    | unlimited validity.   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|-----------------------|
| IB/0018/G | This was an application for a group of variations. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol                                                                                                                                                                                                                                                                     | 15/10/2013 | n/a        |    |                       |
| IA/0017/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - | 13/09/2013 | n/a        |    |                       |
| N/0016    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 15/08/2013 | 11/02/2014 | PL |                       |
| IG/0283   | C.I.z - Changes (Safety/Efficacy) of Human and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 22/03/2013 | n/a        |    |                       |

<div style=\"page-break-after: always\"></div>

|         | Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0014 | Update of sections 4.4 and 4.8 of the SmPC in order to reflect information regarding post-marketing reports of anaphylactic reactions. The Package Leaflet is updated accordingly. In addition, the MAH deleted a sentence regarding laboratory monitoring which is considered redundant. Furthermore, the MAH proposed this opportunity to bring the PI in line with the latest QRD template version 8.3 and introduce a few minor editorial changes. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data | 21/02/2013 | 11/02/2014 | SmPC, Annex II, Labelling and PL | Following a review of the company safety database, 3 spontaneous reports of anaphylactic reaction have been received during the Mozobil post-marketing period of 15 December 2008 through 30 April 2012. Based on the assessment of the cases, a causal relationship with Mozobil could not be excluded. Therefore, section 4.8 of the SmPC have been updated to add anaphylactic reactions, including anaphylactic shock, as new adverse reactions with the frequency 'uncommon' and to include a related warning in section 4.4. The Package leaflet has been updated accordingly. |
| IB/0013 | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                                                                                                                                                                                  | 17/12/2012 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| N/0012  | Update of the local representatives contact details in the Package Leaflet. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                  | 11/07/2012 | 11/02/2014 | PL                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| N/0010  | Update in the local representative for Spain in the package leaflet.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 25/04/2012 | 11/02/2014 | PL                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

|           | change in labelling or package leaflet not with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                              |            |            |          | Minor connected        |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|------------------------|
| IA/0011/G | This was an application for a group of variations. B.I.c.1.a - Change in immediate packaging of the AS - Qualitative and/or quantitative composition B.I.c.3.b - Change in test procedure for the immediate packaging of the AS - Other changes to a test procedure (including replacement or addition) B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor         | 20/04/2012 | n/a        |          | changes to an approved |
| IG/0122   | To update the Detailed Description of the Pharmacovigilance System (DDPS) to version 9, to include a change in the major contractual arrangements. C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the major contractual arrangements with other persons or organisations involved in the fulfilment of pharmacovigilance obligations and described in the DD | 25/11/2011 | n/a        |          |                        |
| IG/0116   | C.I.9.i - Changes to an existing pharmacovigilance system as described in the DDPS - Change(s) to a DDPS following the assessment of the same DDPS in relation to another medicinal product of the same MAH                                                                                                                                                                                                   | 28/10/2011 | 22/12/2011 | Annex II |                        |

<div style=\"page-break-after: always\"></div>

| IA/0007   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 20/10/2011   | n/a        |          |                                                                                                               |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------|---------------------------------------------------------------------------------------------------------------|
| N/0006    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 08/06/2011   | n/a        | PL       |                                                                                                               |
| IA/0005   | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                          | 29/03/2011   | n/a        |          |                                                                                                               |
| IB/0004   | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                                                                                                                                                 | 14/09/2010   | n/a        |          |                                                                                                               |
| IA/0003/G | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits | 09/09/2010   | n/a        |          |                                                                                                               |
| II/0001   | This type II variation concerns an update of section 5.3 of the SmPC to include additional nonclinical                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 21/01/2010   | 15/03/2010 | SmPC and | The MAH submitted the results of the general receptor radioligand binding study, the results of a patch clamp |

<div style=\"page-break-after: always\"></div>

|         | safety pharmacology data regarding the effects of plerixafor on receptors other than CXCR4. These data are provided as part of the FUM 002 as agreed by the CHMP at the time of initial marketing auhtorisation. Sections 4.5 and 5.2 of the SmPC are also updated to include in vitro pharmacokinetics data regarding the evaluation of plerixafor for P-glycoprotein substrate or inhibition potential. Furthermore, the MAH submitted an updated RMP to reflect the new available data. Consequently the version number of the RMP (version 2) was updated in Annex II. The MAH also took the opportunity to update the Product Information in line with the latest QRD template. Update of Summary of Product Characteristics   |            |     | Annex II   | study investigating the effect of plerixafor on Ca-channels expressed in mammalian cells and an evaluation of the P- Glycoprotein substrate and inhibition potential of plerixafor using MDCKII-MDR1 cells. The receptor screening shows that plerixafor has moderate or strong binding affinity for a number of different receptors predominantly located on pre-synaptic nerve endings in the CNS and/or the PNS (N-type calcium channel, potassium channel SKCA, histamine H3, acetylcholine muscarinic M1 and M2, adrenergic alpha-1B and alpha-2C, neuropeptide Y/Y1 and glutamate NMDA polyamine receptors). An interaction of plerixafor with one or more of these receptors could be responsible for plerixafor-induced acute toxicity signs observed in animal studies. This information has been added to section 5.3 of the SmPC. The study submitted evaluating P-gp substrate and inhibition potential of plerixafor in well characterized in vitro cell systems shows that plerixafor is not a substrate for the P-gp transporter and does not inhibit this transporter. Based on the results of this study, sections 4.5 and 5.2 of the SmPC were updated. The results of these studies were also taken into account in an updated RMP. Annex II of the product information was also updated to reflect the new version number of the RMP (version 2). Furthermore, the Product Information was updated in line   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0002 | IA_38_a_Change in test procedure of finished product - minor change to approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 12/01/2010 | n/a |            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |